Logo Logo Logo Logo Logo
  • COMPANY
    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • CONTACT US
  • SCIENCE
    • SNP-Technology
    • Intellectual Property
  • PIPELINE
    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS
    • Press releases
  • CAREERS
  • COMPANY

    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • CONTACT US
  • SCIENCE

    • SNP-Technology
    • Intellectual Property
  • PIPELINE

    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS

    • Press releases
  • CAREERS

Press Release 2020

September 1, 2020

 

OCULIS ESTABLISHES PRESENCE IN U.S. AND APPOINTS SYLVIA CHEUNG AS CHIEF FINANCIAL OFFICER 

August 10, 2020

 

OCULIS REPORTS POSITIVE TOP-LINE DATA FROM SKYGGN (PHASE 2) TRIAL WITH OCS-01 FOR TREATING INFLAMMATION AND PAIN FOLLOWING CATARACT SURGERY

July 27, 2020

 

OCULIS ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA FOR OCS-01 IN TWO OPHTHALMOLOGY INDICATIONS

Contact us

Oculis Switzerland
Corporate Headquarters
EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne
Switzerland

+41 21 711 3970

 

Oculis Iceland
Alfheimar 74
6th Floor
104 Reykjavik
Iceland

+354 546 4440

Copyright © 2020 Oculis SA.

    © Oculis – Private policy

    © L’autreagence 2019